Scancell, the cancer immunotherapy developer, has appointed David Schilansky as financial adviser and interim chief, signalling a management-level change. The move suggests a temporary leadership adjustment and potential strategic or financial review but contains no financial metrics or definitive strategic actions; immediate market impact is likely limited.
Scancell, the cancer immunotherapy developer, has appointed David Schilansky as financial adviser and interim chief, signalling a management-level change. The move suggests a temporary leadership adjustment and potential strategic or financial review but contains no financial metrics or definitive strategic actions; immediate market impact is likely limited.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
neutral
Sentiment Score
0.00
